Capecitabine (Xeloda)
Chemotherapy · Approved since 1998
Description
Capecitabine is an oral fluoropyrimidine chemotherapy agent used extensively in colorectal cancer treatment across multiple settings including adjuvant therapy for stage III colon cancer and treatment of metastatic colorectal cancer. It is commonly used as monotherapy or in combination regimens such as CapeOX (capecitabine plus oxaliplatin) for both adjuvant and metastatic settings. The drug is particularly valuable in patients who cannot tolerate intravenous 5-fluorouracil infusions, and dosing may require adjustment based on DPYD gene polymorphisms that affect fluoropyrimidine metabolism.
Mechanism of Action
Capecitabine is a prodrug that undergoes sequential enzymatic conversion to 5-fluorouracil (5-FU) preferentially in tumor tissues through the enzyme thymidine phosphorylase. Once converted to 5-FU, it inhibits thymidylate synthase, blocking DNA synthesis and repair, while also incorporating into RNA to disrupt cellular function, ultimately leading to cancer cell death.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Xeloda |
| Category | Chemotherapy |
 Status | FDA Approved |
 EMA Status | EMA Approved |
 Spain Access | Funded by SNS approved in CRC |
| Administration | Oral |
| Year Approved | 1998 |
| Clinical Trials | 493 |
Regimens with this Drug
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.